Johnson & Johnson's Late-Breaking Results From Its PALOMA-2 Study Of Subcutaneous Amivantamab In Combination With Lazertinib Show Clinically Meaningful Antitumor Response And Improved Safety Profile In Patients With EGFR-Mutated Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson announced new Phase 2 data from the PALOMA-2 study showing that subcutaneous amivantamab combined with lazertinib provides a clinically meaningful antitumor response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer. The results were presented at the 2024 ASCO Annual Meeting.
June 03, 2024 | 6:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's new Phase 2 data from the PALOMA-2 study shows that subcutaneous amivantamab combined with lazertinib provides a clinically meaningful antitumor response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer.
The positive results from the PALOMA-2 study, including improved safety and efficacy of subcutaneous amivantamab combined with lazertinib, are likely to boost investor confidence in Johnson & Johnson. This could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100